fMRI Analysis: Change in Anterior Insula Region
| Group | Value (percentage of area activation) |
|---|---|
| Adults With PTSD (18-55): Drug | -12.6 |
| Adults With PTSD (18-55): Placebo | -1.6 |
| Adults Without PTSD (18-55): Drug | 10.6 |
| Adults Without PTSD (18-55): Placebo | -7.8 |
Trial · Interventional
CompletedPhase 2Results postedRegistry dataUnited States
1 trial · 1 completed · 1 with posted results
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
The investigators will use multiple methods (including Oxytocin intranasal inhalation, neuroimaging, behavioral measures, peripheral hormone measurements) to examine how individuals' behavior, cognition, and brain function is impacted by the neuro-hormone Oxytocin. Specifically, the investigators plan to evaluate the influence of Oxytocin administration on affective processing in non-trauma exposed and trauma-exposed adults (both with and without posttraumatic stress disorder, PTSD).
Experimental
Healthy adult controls (18-55)
Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
Experimental
Adults with PTSD (18-55)
Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
Experimental
Trauma-exposed/no-PTSD adults (18-55)
Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
Outcomes the sponsor listed as primary.
fMRI Analysis: Change in Anterior Insula Region
Time frame · 1 week; fMRI data collected at second and third visits, one week apart
Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.
fMRI Analysis: Change in Accumbens Region
Time frame · 1 week; fMRI data collected at second and third visits, one week apart
Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.
fMRI Analysis: Change in Amygdala Region
Time frame · 1 week; fMRI data collected at second and third visits, one week apart
Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.
fMRI Analysis: Change in dACC Region
Time frame · 1 week; fMRI data collected at second and third visits, one week apart
Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.
fMRI Analysis: Change in mOFC Region
Time frame · 1 week; fMRI data collected at second and third visits, one week apart
Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.
fMRI Analysis: Change in rACC Region
Time frame · 1 week; fMRI data collected at second and third visits, one week apart
Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.
fMRI Analysis: Change in vmPFC Region
Time frame · 1 week; fMRI data collected at second and third visits, one week apart
Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.
Salivary Oxytocin
Time frame · Within session (30 min) and between sessions (1 week); saliva samples collected twice (before and after OT administration) at both second and third visits, one week apart
Expect within-session (30 min) increase in peripheral salivary oxytocin level during OT sessions (within-session), and higher OT levels in oxytocin administration vs. placebo sessions. Peripheral OT levels measured with Salivettes (sterile cotton participants will be asked to chew on for 1 minutes).
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
| Group | Value (percentage of area activation) |
|---|---|
| Adults With PTSD (18-55): Drug | -12.6 |
| Adults With PTSD (18-55): Placebo | -1.6 |
| Adults Without PTSD (18-55): Drug | 10.6 |
| Adults Without PTSD (18-55): Placebo | -7.8 |
| Group | Value (percentage of area activation) |
|---|---|
| Adults With PTSD (18-55): Drug | 7.6 |
| Adults With PTSD (18-55): Placebo | -7.9 |
| Adults Without PTSD (18-55): Drug | -17.2 |
| Adults Without PTSD (18-55): Placebo | -12.7 |
| Group | Value (percentage of area activation) |
|---|---|
| Adults With PTSD (18-55): Drug | -3.8 |
| Adults With PTSD (18-55): Placebo | -9.1 |
| Adults Without PTSD (18-55): Drug | 14.5 |
| Adults Without PTSD (18-55): Placebo | -6.7 |
| Group | Value (percentage of area activation) |
|---|---|
| Adults With and Without PTSD (18-55): Drug | -20.9 |
| Adults With and Without PTSD (18-55): Placebo | -16.4 |
| Adults Without PTSD (18-55): Drug | -4.8 |
| Adults Without PTSD (18-55): Placebo | -30.2 |
| Group | Value (percentage of area activation) |
|---|---|
| Adults With PTSD (18-55): Drug | 1.5 |
| Adults With PTSD (18-55): Placebo | 2.5 |
| Adults Without PTSD (18-55): Drug | 1.7 |
| Adults Without PTSD (18-55): Placebo | -8.1 |
| Group | Value (percentage of area activation) |
|---|---|
| Adults With PTSD (18-55): Drug | -5.9 |
| Adults With PTSD (18-55): Placebo | -4.4 |
| Adults Without PTSD (18-55): Drug | -0.2 |
| Adults Without PTSD (18-55): Placebo | -16.3 |
| Group | Value (percentage of area activation) |
|---|---|
| Adults With and Without PTSD (18-55): Drug | -3.8 |
| Adults With and Without PTSD (18-55): Placebo | -6.8 |
| Adults Without PTSD (18-55): Drug | -3.3 |
| Adults Without PTSD (18-55): Placebo | -16.0 |
| Group | Value |
|---|---|
| Adults With PTSD (18-55): Drug | not posted |
| Adults With PTSD (18-55): Placebo | not posted |
| Adults Without PTSD (18-55): Drug | not posted |
| Adults Without PTSD (18-55): Placebo | not posted |
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| Adults With PTSD (18-55)Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril). Oxytocin: See arm/group descriptions for dosage amount and procedure. Placebo: See arm/group descriptions for dosage amount and procedure. | 0 / 9 | 0 / 9 | 0 / 9 |
| Trauma-exposed/No-PTSD Adults (18-55)Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril). Oxytocin: See arm/group descriptions for dosage amount and procedure. Placebo: See arm/group descriptions for dosage amount and procedure. | 0 / 2 | 0 / 2 | 0 / 2 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
No study cites this trial.
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated